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The persistent infection of high-risk HPV usually resulted in cervical cancer, which
ranks second in the most common malignant tumors threatening women’s health.
About 500,000 people are found to suffering from cervical cancer globally, with
200,000 fatal cases each year. And there is about 13 million people suffered from
cervical cancer in China yearly. Among the more than 15 kinds of high-risk HPVs
involved in cervical cancer, detection rate of HPV16/18 reaches about 70%. HPV
vaccine is considered as the most effective means in prophylaxis and control of
cervical disease. However, vaccine candidate available at present only cover the
HPV16 and 18 due to cost and manufacturing difficulties, which is not good
enoμgh for clinical usage. Therefore, the development of vaccines candidate
which can prevent more HPVs including HPV16/18 infect could further reduce the
incidence of cervical cancer. Multivalent vaccines, L2 vaccine, and chimeric
particles vaccine is currently the mainstream of vaccine developments. Thus, the
studies of broad-spectrum neutralizing monoclonal antibodies and corresponding
epitopes could improve the vaccine development against HPVs.
To screen the broad-spectrum neutralizing monoclonal antibodies of HPV, proper
immunizing program was explored in this study, with viral type, state of
immunogen, dosage, adjutants, immune intervals and dosage all considered. The
final immunizing program established are as following: The crossing immunization
using VLPs of different types, dose of 1-10 μg per mouse once and three weeks
of immune intervals with Freund's adjuvant. With the combination of ELISA and
neutralization detection in hybridoma technique, we get three mAb clones (13A10,
12B9 and 4H4) capable of neutralizing against two or more viral types at last.
We further analyzed the properties of three mAb clones in ELISA, finding that the
entire clones bind with VLPs of A9 respectively: clone 13A10 binds with VLPs of













with HPV 16, 31 and 33. Feathers of conformational dependent were identified
with Western blot and neutralizing potent against different vial types were
analyzed with pseudoviruses neutralization model: clone 13A10 could neutralize
with pseudoviruses of HPV16/58/31/33, clone 12B9 with HPV33/58 and 4H4 with
HPV16/31/33. The immunodominancy was analyzed in blocking ELISA with rabbit
anti sera, the clinical sera of patients infected by HPV, sera of people injected
HPV vaccine candidates and type-specific mAbs of HPV. We found that clone
13A10 is immunodominant, which could block half sera of HPV58 with the single
blocking rate at 80%. It can be inferred from the poor blocking rate against clinical
sera that clone 12B9 and 4H4 were not immunodominant, despite the high
blocking rate against HPV 33-specific mAb of clone 12B9. The binding affinity
with antigen is analyzed by biological sensor, found that the affinity of clone
13A10 against VLP of HPV 58 is 10-10mol/L, which is equal to type-specific
mAbs.
We further analyzed the antigenic sites recognized by clone 13A10 due to the
broad-spectrum neutralizing potent, immunodominacy and high binding affinity.
Firstly, the proportion of 13A10 binding VLP was detected as 2.5:1(n:n) by GFC-
HPLC and AUC. Secondly, structures of HPV58 pentamer and 13A10 were
simulated by homology modeling, followed by epitopes prediction in HPV16 and
58. Result shows that the amino acids residue of 55-59,442-433,177 and 348
were involved. Together with mutant protein analysis, the definite amino acids
were localized into Ser343,Leu344,Cys345,Ala346,Ile348,Ser349 and Thr350
eventually.At last,we determined that Ile348 is the epitope of 13A10.
Findings from this study provide necessary resources and effective approaches
for molecular designing and quality control in universal vaccine development. It
also highlights the dominancy of conformational-dependent epitopes in HPV.
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